デフォルト表紙
市場調査レポート
商品コード
1412606

自己免疫疾患用IVDおよびLDT市場:技術別、用途別-2024-2030年の世界予測

IVD & LDT For Autoimmune Diseases Market by Technology (Clinical Chemistry, Coagulation, Hematology), Application (Addison's Disease, Alopecia Areata, Ankylosing Spondylitis) - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 199 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.33円
自己免疫疾患用IVDおよびLDT市場:技術別、用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

自己免疫疾患用IVDおよびLDT市場規模は2023年に172億7,000万米ドルと推計され、2024年には183億米ドルに達し、CAGR 5.22%で2030年には246億8,000万米ドルに達すると予測されます。

自己免疫疾患用IVDおよびLDTの世界市場

主な市場の統計
基準年[2023] 172億7,000万米ドル
予測年[2024] 183億米ドル
予測年 [2030] 246億8,000万米ドル
CAGR(%) 5.22%
IVD &LDT For Autoimmune Diseases Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは自己免疫疾患用IVDおよびLDT市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、自己免疫疾患用IVDおよびLDT市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-自己免疫疾患用IVDおよびLDT市場の市場規模および予測は?

2-自己免疫疾患用IVDおよびLDT市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-自己免疫疾患用IVDおよびLDT市場における技術動向と規制の枠組みは?

4-自己免疫疾患用IVDおよびLDT市場における主要ベンダーの市場シェアは?

5-自己免疫疾患用IVDおよびLDT市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 経済における自己免疫疾患の発生率の増加
      • 自己免疫疾患の診断検査に関する意識の向上
      • ヘルスケアインフラの発展の加速とヘルスケア支出の増大
    • 抑制要因
      • 神経精神科以外の健康上の問題に関する懸念
    • 機会
      • IVD分野における技術の進歩
      • 体外診断(IVD)検査キットの開発における共同成長の高まり
    • 課題
      • IVDおよびLDTに対する厳しい規制
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 自己免疫疾患用IVDおよびLDT市場:技術別

  • 臨床化学
  • 凝固
  • 血液学
  • 免疫学的検査
  • 微生物学
  • 分子診断学

第7章 自己免疫疾患用IVDおよびLDT市場:用途別

  • アジソン病
  • 円形脱毛症
  • 強直性脊椎炎
  • 抗リン脂質抗体症候群
  • クローン病
  • 1型糖尿病
  • 多発性硬化症
  • ナルコレプシー
  • 乾癬
  • 関節リウマチ
  • 全身性エリテマトーデス
  • 全身性硬化症
  • 潰瘍性大腸炎
  • ぶどう膜炎

第8章 南北アメリカの自己免疫疾患用IVDおよびLDT市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の自己免疫疾患用IVDおよびLDT市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの自己免疫疾患用IVDおよびLDT市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Adaptive Biotechnologies Corporation
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories, Inc.
    • bioMerieux, Inc.
    • Corgenix, Inc.
    • Creative Biolabs Inc.
    • Diasorin S.P.A.
    • in.vent Diagnostica GmbH
    • Johnson & Johnson Services, Inc.
    • Microbix Biosystems Inc.
    • PerkinElmer, Inc.
    • Roche Diagnostics Corporation
    • SQI Diagnostics Inc.
    • Thermo Fisher Scientific Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET DYNAMICS
  • FIGURE 7. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 6. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COAGULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ALOPECIA AREATA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTIPHOSPHOLIPID ANTIBODY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIABETES TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY NARCOLEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 114. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 115. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET LICENSE & PRICING
目次
Product Code: MRR-ED54C46E881C

[199 Pages Report] The IVD & LDT For Autoimmune Diseases Market size was estimated at USD 17.27 billion in 2023 and expected to reach USD 18.30 billion in 2024, at a CAGR 5.22% to reach USD 24.68 billion by 2030.

Global IVD & LDT For Autoimmune Diseases Market

KEY MARKET STATISTICS
Base Year [2023] USD 17.27 billion
Estimated Year [2024] USD 18.30 billion
Forecast Year [2030] USD 24.68 billion
CAGR (%) 5.22%
IVD & LDT For Autoimmune Diseases Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the IVD & LDT For Autoimmune Diseases Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the IVD & LDT For Autoimmune Diseases Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the IVD & LDT For Autoimmune Diseases Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., bioMerieux, Inc., Corgenix, Inc., Creative Biolabs Inc., Diasorin S.P.A., in.vent Diagnostica GmbH, Johnson & Johnson Services, Inc., Microbix Biosystems Inc., PerkinElmer, Inc., Roche Diagnostics Corporation, SQI Diagnostics Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the IVD & LDT For Autoimmune Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Clinical Chemistry
    • Coagulation
    • Hematology
    • Immunoassays
    • Microbiology
    • Molecular Diagnostics
  • Application
    • Addison's Disease
    • Alopecia Areata
    • Ankylosing Spondylitis
    • Antiphospholipid Antibody Syndrome
    • Crohn's Disease
    • Diabetes Type 1
    • Multiple Sclerosis
    • Narcolepsy
    • Psoriasis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Ulcerative Colitis
    • Uveitis
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the IVD & LDT For Autoimmune Diseases Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the IVD & LDT For Autoimmune Diseases Market?

3. What are the technology trends and regulatory frameworks in the IVD & LDT For Autoimmune Diseases Market?

4. What is the market share of the leading vendors in the IVD & LDT For Autoimmune Diseases Market?

5. Which modes and strategic moves are suitable for entering the IVD & LDT For Autoimmune Diseases Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. IVD & LDT For Autoimmune Diseases Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of autoimmune disorders in economies
      • 5.1.1.2. Increasing awareness regarding diagnostic tests for autoimmune diseases
      • 5.1.1.3. Rising development of healthcare infrastructure and growing healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding extra-neuropsychiatric health problems
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of IVD
      • 5.1.3.2. Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations of IVDs & LDTs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. IVD & LDT For Autoimmune Diseases Market, by Technology

  • 6.1. Introduction
  • 6.2. Clinical Chemistry
  • 6.3. Coagulation
  • 6.4. Hematology
  • 6.5. Immunoassays
  • 6.6. Microbiology
  • 6.7. Molecular Diagnostics

7. IVD & LDT For Autoimmune Diseases Market, by Application

  • 7.1. Introduction
  • 7.2. Addison's Disease
  • 7.3. Alopecia Areata
  • 7.4. Ankylosing Spondylitis
  • 7.5. Antiphospholipid Antibody Syndrome
  • 7.6. Crohn's Disease
  • 7.7. Diabetes Type 1
  • 7.8. Multiple Sclerosis
  • 7.9. Narcolepsy
  • 7.10. Psoriasis
  • 7.11. Rheumatoid Arthritis
  • 7.12. Systemic Lupus Erythematosus
  • 7.13. Systemic Sclerosis
  • 7.14. Ulcerative Colitis
  • 7.15. Uveitis

8. Americas IVD & LDT For Autoimmune Diseases Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific IVD & LDT For Autoimmune Diseases Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa IVD & LDT For Autoimmune Diseases Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Adaptive Biotechnologies Corporation
    • 12.1.2. Agilent Technologies Inc.
    • 12.1.3. Bio-Rad Laboratories, Inc.
    • 12.1.4. bioMerieux, Inc.
    • 12.1.5. Corgenix, Inc.
    • 12.1.6. Creative Biolabs Inc.
    • 12.1.7. Diasorin S.P.A.
    • 12.1.8. in.vent Diagnostica GmbH
    • 12.1.9. Johnson & Johnson Services, Inc.
    • 12.1.10. Microbix Biosystems Inc.
    • 12.1.11. PerkinElmer, Inc.
    • 12.1.12. Roche Diagnostics Corporation
    • 12.1.13. SQI Diagnostics Inc.
    • 12.1.14. Thermo Fisher Scientific Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing